±í1 ÊÜÕß¶¯Îï¸øÓ費ͬ´¦ÀíºóÐÐͬÖÖÆ¤Æ¬ÒÆÖ²¡¢Æ¤Æ¬´æ»îʱ¼äͳ¼Æ±í

¡¡¡¡×¢£ºÊÜÕßÊóÔÚÆ¤Æ¬ÒÆÖ²Ç°£³£°Ìì¸øÓè900radÖÂËÀÁ¿Ù¤ÂêÉäÏßÕÕÉ䣬ͬʱÈç±í1Ëùʾ£¬ÓÚÕÕÉäºó£¶hÄÚ»ØÊ䲻ͬµÄϸ°û¡£±íÖУí£ó£ôµÄ ¼ÆËã »ùÓÚ£³´Î²»Í¬µÄʵÑé½á¹û£»*p£¼0.005×飱ºÍ×飰¼ä£»p£¼0.0001×飱ºÍ×飳¼ä¡£mst£¬median survival time£¬¼´ÖÐÊý´æ»îʱ¼ä¡£dc£¬Ö¸¾Í¬ÖÖÒÆÖ²¼¤»îµÄÊ÷ͻ״ϸ°û£¬¼´balb/cСÊóÏȽÓÊÜͬÖÖÆ¤Æ¬ÒÆÖ²£¨¹©ÕßΪc57Ê󣩣¬10ÌìºóȡƢϸ°û£¬¾ÁܰÍϸ°û·Ö²ãÒº·Ö²ãÀëÐĵõ½µ¥ºËϸ°û£¬²¢ÓôÅÖé±ê¼ÇµÄ¿¹Ð¡Êópan-t¿¹ÌåÒõÐÔ·Öѡȥ³ý£ôϸ°ûºóµÃµ½µÄϸ°û¡£bmc£¬ÎªÍ¬Æ·ÏµµÄbalb/cСÊó¹ÇËèϸ°û
2.3 ¼¤»îµÄdcϸ°ûÓÕµ¼¹©ÕßÌØÒìÐÔÒÆÖ²ÄÍÊÜ ÎªÖ¤Êµ¼¤»îµÄdcϸ°ûÓÕµ¼µÄÊǹ©ÕßÌØÒìÐÔµÄÄÍÊÜ£¬ÎÒÃÇÈ¡Î޹صĹ©Õß129ÊóµÄβ²¿Æ¤Æ¬£¬Èç±í1×é3Ëùʾ£¬Óë×é1Ïà±È£¬ÊÜÕߵĴ¦ÀíÍêÈ«Ïàͬ£¬µ«Æ¤Æ¬À´×ÔÎ޹صÄ129Ê󣬸ÃÒÆÖ²Æ¤Æ¬ÔÚµÚ10Ìì¾ù±»ÍêÈ«Åų⣬mst=10Ì죬Óë×é1Ïà±È£¬²îÒìÓÐÏÔÖøÐÔ£¨p£¼0.001£©¡£
Ïà·´£¬¹©ÕßÕÕÉäºó½ö¸øÓè¹ÇËèϸ°û£¬²úÉúµÄÄÍÊÜÊÇ·ÇÌØÒìÐԵģ¬Èç×é2¡¢×é4Ëùʾ£¬ÊÜÕß¶Ôc57ÊóºÍ129ÊóµÄƤƬ¾ù²úÉúÄÍÊÜ£¬Á½Õßmst¾ù´ïµ½28Ì죬²îÒìÎÞͳ¼ÆÑ§ÒâÒ壨p£¾0.05£©¡£
2.4 ÒÆÖ²Æ¤Æ¬²¿Î»²¡Àí×é֯ѧ ·ÖÎö Èçͼ3Ëùʾ£¬µÚ11Ì죬×é0(a)£¬×é3£¨c£©ÊÜÕ߯¤Æ¬ÍêÈ«±»Åų⣬¾µÏ¹۲ì¼û´óÁ¿Ñ×֢ϸ°û½þÈó£¬×é0(a)ƤƬºÍÊÜÕßÒÆÖ²²¿Î»Ïà·ÖÀ룻Ïà·´£¬´Ëʱ×é1(b)ƤƬÉú³¤Á¼ºÃ£¬¾µÏ¼ûÒÆÖ²Æ¤Æ¬ºÍÊÜÕßÒÆÖ²²¿Î»Ã»ÓÐÍÑÀëÇãÏò£¬Ò²Î´¼ûÃ÷ÏÔÑ×֢ϸ°û½þÈó¡£

2.5 ʵÑé×éµÄÃâÒßѧ¹¦ÄÜ״̬µÄÁ÷ʽϸ°û·ÖÎö½á¹û ·Ö±ðÓÚÆ¤Æ¬ÒÆÖ²ÊõºóµÚ11¡¢19¡¢23Ì죬ȡ×é0¡¢×é1ÒÆÖ²ÊÜÕßÍâÖÜѪ£¬ÓÃÁ÷ʽϸ°û·ÖÎöÍâÖÜѪcd4+»òÕßcd8+tϸ°ûÒÔ¼°Á½ÕߵıÈÀý¡£Èç±í2Ëùʾ£¬ÓÚµÚ11Ì죬×é0ºÍ×é1¼ä£¬cd4+¡¢cd8+ϸ°ûÒÔ¼°Á½ÕߵıÈÀý²îÒìÓÐÏÔÖøÐÔ£»µÚ11¡¢19¡¢23Ì죬cd4+¡¢cd8+ϸ°ûÒÔ¼°Á½ÕߵıÈÀýÔÚ×é1ÊÜÕß×éÄÚ²îÒìÒ²ÓÐÏÔÖøÐÔ£¨p£¼0.01£©¡£¿É¼ûÔÚÃâÒßÖØ½¨¹ý³ÌÖУ¬×é1µÄcd4+¸¨ÖúÐÔtϸ°ûÓÚÒÆÖ²ºó30Ì죬ÔÚ±ÈÀýºÍ¾ø¶ÔÊýÄ¿ÉÏÒѾÍêÈ«»Ö¸´£»´Ócd4+/cd8+ϸ°û±ÈÖµ¿´£¬¹ÇËèÒÆÖ²ºó£¬±ÈÖµÃ÷ÏÔÉý¸ßÁË£¬Ò»·½ÃæÊÇcd4+µÄtϸ°û±ÈÀýÔö¼ÓÁË£¬Í¬Ê±£¬cd8+tϸ°û±ÈÀý¼õÉÙÁË£¬cd8+µÄtϸ°û¼õÉٵķù¶È³¬¹ýÁËcd4+µÄtϸ°ûÔö¼ÓµÄ·ù¶È£¬½á¹ûcd4+/cd8+µÄ±ÈÖµ£¬×é1Óë×é0Ïà±È£¬Ôö¼ÓÁË3±¶×óÓÒ¡£ÔÚÍêÈ«ÅųâµÄ23Ì죬ÆäÖµ´ïµ½×î¸ß·å£¨7.87£©¡£
±í2 Á÷ʽϸ°û·ÖÎö½á¹û

¡¡¡¡×¢£ºÓÚµÚ11Ì죬×é0ºÍ×é1¼ä£¬cd4+¡¢cd8+ϸ°ûÒÔ¼°Á½ÕߵıÈÀý²îÒìÓÐÏÔÖøÐÔ£»µÚ11¡¢19¡¢23Ì죬cd4+¡¢cd8+ϸ°ûÒÔ¼°Á½ÕߵıÈÀýÔÚ×é1ÊÜÕß×éÄÚ²îÒìÒ²ÓÐÏÔÖøÐÔ
3 ÌÖÂÛ
Ƥ·ôÒÆÖ²ÊǷdz£ÑϸñµÄÒÆÖ²Åų⶯ÎïÄ£ÐÍ£¬Æ¤·ôÊÇÈ«Éí¸÷ÖÖÆ÷¹Ù×éÖ¯ÖÐ×îÈÝÒ×±»ÅųâµÄ×éÖ¯£¬¶øÇÒÆ¤·ôÒÆÖ²Ö±¹Û£¬²Ù×÷Ïà¶Ô¼òµ¥£Û11£Ý£¬ËùÒÔÎÒÃÇÑ¡ÔñËü×÷Ϊ¶¯ÎïÄ£ÐÍ¡£ÔÚ²»Ê¹ÓÃϵͳÐÔÃâÒßÒÖÖÆ¼ÁµÄÇé¿öÏ£¬ÎÒÃÇÔÚСÊ󯤷ôÒÆÖ²Ä£ÐÍÖгɹ¦ÓÕµ¼¹©ÕßÌØÒìÐÔÃâÒßÄÍÊÜ£¬Ê¹Æ¤Æ¬´æ»îʱ¼äÃ÷ÏÔÑÓ³¤£¬¶ÔÓÚc57bl/6À´Ô´µÄƤƬ£¬Æämst´ï20Ì죻Ïà·´£¬¶ÔÓÚÎÞ¹Ø129ÊóÀ´Ô´µÄƤƬ£¬Æämst=10Ìì¡£¿ÉÄܵÄÄÍÊÜ»úÖÆÊǸ´Ôӵģº£¨1£©¿ÉÄÜÊÇÓÉÓھͬÖÖÒÆÖ²¼¤»îµÄdcsЯ´ø¹©ÕßÌØÒìÐÔ¿¹Ô£¬¾Î²¾²Âö»ØÊä½øÈëÊÜÊóÌåÄÚ£¬È»ºóËæÑªÒºÑ»·¹é³²µ½ÊÜÕßÐØÏÙÖУ¬Ìá³Ê¹©Õß¿¹Ô²ÎÓëÒõÐÔÑ¡Ôñ¹ý³Ì£¬Ê¹ÊÜÕßÔÚÃâÒßÖØ½¨¹ý³ÌÖУ¬´ó²¿·Ö¹©Õß·´Ó¦ÐÔµÄtÁܰÍϸ°ûÔÚÐØÏÙˮƽ¾ÒõÐÔÑ¡ÔñÓÉÓÕµ¼µòÍö¿Ë¡Çå³ýºÍ¿Ë¡ÎÞÄܵȻúÖÆÈ¥³ýµô£¬´Ó¶øÓÕµ¼¶Ô¹©Õ߯¤Æ¬µÄÄÍÊÜ£¬Í¬Ê±£¬ÔÚÃâÒßÖØ½¨µÄ¹ý³ÌÖУ¬ÊÜÕßÄܱ£³Ö¶ÔÆäËû¿¹ÔµÄÕý³£ÃâÒßÓ¦´ð£»£¨2£©Ò²¿ÉÄÜÊǹ©Õß¿¹Ô½øÈëÐØÏÙºó£¬ÓÕµ¼µ÷½ÚÐÔtϸ°ûtregϸ°û¶Ô¹©Õß²úÉúÌØÒìÐÔµÄÃâÒßÄÍÊÜ¡££¨3£©»¹¿ÉÄÜÊÇÓÉÓÚͬÖÖÒÆÖ²¼¤»îµÄdcsЯ´ø¹©ÕßÌØÒìÐÔ¿¹Ô½øÈëÌåÄں󣬼¤»îͬÖÖ·´Ó¦ÐÔtϸ°û»ØÁ÷ÈëÐØÏÙËùÖ¡£
´Ó×é3µÄ½á¹û¿ÉÖª£¬½ÓÊÜÁËÖÂËÀÁ¿ÕÕÉäµÄÊÜÊóÔÚ¾¹ý30ÌìµÄÃâÒßÖØ½¨ºó£¬ÓÚµÚ10Ìì¾ÍÍêÈ«ÅųâÁËÎÞ¹Ø129ÊóµÄƤƬ£¬Ò»·½ÃæËµÃ÷¸ÃÄÍÊÜÓÕµ¼·½°¸µÄÌØÒìÐÔ£»Í¬Ê±Ò²±íÃ÷£¬ÊÜÊó¾ß±¸ÁËÍêÕûµÄÃâÒß¹¦ÄÜ£¬Á÷ʽϸ°û·ÖÎöµÄ½á¹ûÒ²½øÒ»²½Ö¤ÊµÁËÊÜÊóµÄÃâÒß¹¦ÄÜ£¬Èç±í2Ëùʾ£¬ÔÚÃâÒßÖØ½¨¹ý³ÌÖУ¬×é1µÄcd4+¸¨ÖúÐÔtϸ°ûÓÚÒÆÖ²ºó30Ì죬ÔÚ±ÈÀýºÍ¾ø¶ÔÊýÄ¿ÉÏÒѾÍêÈ«»Ö¸´£»´Ócd4/cd8ϸ°û±ÈÖµ¿´£¬ÓÉÓÚÍâÖÜcd4/cd8µÄ±ÈÖµÊÇÓÉÐØÏÙµÄ΢»·¾³¾ö¶¨µÄ£¬ÐØÏÙµÄÊä³ö¶ÔÓڸñÈÖµÓоö¶¨ÐÔµÄ Ó°Ïì £¬ÔÚÕý³£µÄ³ÉÄêСÊ󣬯äÖµ½éÓÚ2¡«4Ö®¼ä£Û12£Ý£»¹ÇËèÒÆÖ²ºó£¬±ÈÖµÃ÷ÏÔÉý¸ßÁË¡£ÓÉÓÚcd4+µÄϸ°ûʶ±ðmhc class ii·Ö×ÓºÍÍâÔ´ÐԵĿ¹ÔëÄÐγɵĸ´ºÏÌ壬Òò´ËÍÆ¶Ï¿ÉÄÜÊÇÓÉÓÚͬÖÖ¼¤»îµÄdcsЯ´øÍ¬ÖÖÒìÐÍ¿¹Ô·Ö×Ó½øÈëÐØÏÙºó£¬Ò»·½ÃæÍ¨¹ýÐØÏÙµÄÒõÐÔÑ¡ÔñÓÕµ¼Ï¸°û¶¾ÐÔµÄcd8+tϸ°ûµòÍö£¬Òò´ËÍâÖÜcd8+tϸ°ûµÄ±ÈÀý¼õÉÙÁ˽üÒ»°ë£»Í¬Ê±£¬ÓÉÓڸ÷½°¸ÓÕµ¼µÄÊDz»ÍêÈ«µÄÄÍÊÜ£¬Æämst=20Ìì£¬ÒÆÖ²Êõºó²»¿É±ÜÃâµÄ·¢ÉúÅųⷴӦ£¬½«µ¼ÖÂÁËcd4+µÄtϸ°ûÊýÄ¿Ôö¼Ó£¬ÔÚÍêÈ«ÅųâµÄ23Ì죬ÆäÖµ´ïµ½×î¸ß·å¡£
Ƥ·ôÒÆÖ²ÓиßÅųâÐÔÇÒ²Ù×÷¼òµ¥£¬ÊÇÁ¼ºÃµÄÒÆÖ²¶¯ÎïÄ£ÐÍ£¬µ«ÊÇÔÚÁÙ´²É϶àΪ×ÔÌ寤·ôÒÆÖ²£¬Òò´Ë£¬ÎÒÃÇÒ²ÉèÏëÔÚ½ñºóµÄʵÑéÖг¢ÊÔÐÄÔàÒÆÖ²¡¢ÉöÔàÒÆÖ²µÈÆäËûµÄÒÆÖ²Ä£ÐÍÀ´½øÒ»²½Ñé֤ʵÑé½á¹û£¬ÆÚ´ýÄܶԽ«À´µÄÁÙ´²ÊµÌåÆ÷¹ÙÒÆÖ²Ìṩ¸üÓÐÒâÒåµÄ ²Î¿¼ £»¶ÔÓÚ¼¤»îµÄdcϸ°û³ÊµÝµÄ¹©Õß¿¹Ô£¬ÎÒÃÇҲϣÍûÄÜÔÚ½ñºóµÄʵÑéÖнøÒ»²½ÌáÈ¡¡¢´¿»¯£¬ÒÔÆÚ´ý·ÖÎöÓÕµ¼ÒÆÖ²ÄÍÊܵÄÓÅÊÆ±íλ£»Í¬Ê±£¬ÎÒÃÇÒ²ÔÚÉè¼Æ½øÒ»²½µÄʵÑéÀ´Ñé֤ǰÎÄËùÊöµÄÓÕµ¼¸ÃÃâÒßÄÍÊÜ·½°¸µÄ¿ÉÄÜ»úÖÆ¡£
(ÖÂл£º¸Ðл±±¾©´óѧÈËÃñ Ò½Ôº ¸Î²¡ Ñо¿ ËùµÄκÀ´½ÌÊÚ£¬¸ßÑà½ÌÊÚÌṩָµ¼ºÍʵÑéµÄ²¿·Ö³¡Ëù£»´ÔÐñÀÏʦÌṩʵÑéµÄ¼¼ÊõÖ§³Ö)
¡¾²Î¿¼ ÎÄÏ× ¡¿
1 soulillou jp.how and when will cardiac xenotransplantation enter the clinic? the recurrent debate has gained in realism.nat clin pract cardiovasc med£¬2005 nov£»2(11)£º550-551.
2 duncan md£¬wilkes ds.transplant-related immunosuppression£ºa review of immunosuppression and pulmonary infections.proc am thorac soc£¬2005£¬2(5)£º449-455.
3 rezzani r.exploring cyclosporine a-side effects and the protective role-played by antioxidants£ºthe morphological and immunohistochemical studies.histol histopathol£¬2006£¬21(3)£º301-316.
4 hale da£¬dhanireddy k£¬bruno d£¬et al.induction of transplantation tolerance-the potential of regulatory t cells.transpl immunol£¬2005£¬14(3-4)£º225-230.epub 2005£¬apr 26.
5 raimondi g£¬thomson aw.dendritic cells£¬tolerance and therapy of organ allograft rejection.contrib nephrol£¬2005£¬146£º105-120.
6 yong-jun liu.a unified theory of central tolerance in the thymus.trends in immunology£¬2006.
7 mark a wallet£¬pradip sen£¬phd£¬roland tisch.immunoregulation of dendritic cells.clinical medicine & research£¬2005£¬3£º166-175.
8 xue y£¬murdjeva m£¬okret s£¬et al.inhibition of i-ad-£¬but not db-restricted peptide-induced thymic apoptosis by glucocorticoid receptor antagonist ru486 in t cell receptor transgenic mice.eur j immunol£¬1996£¬26(2)£º428-434.
9 garrovillo m£¬ali a£¬oluwole sf. indirect allorecognition in acquired thymic tolerance£ºinduction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells.transplantation£¬1999£¬68£º1827.
10 ali a£¬garrovillo m£¬oluwole oo£¬et al.mechanisms of acquired thymic tolerance£ºinduction of transplant tolerance by adoptive transfer of in vivo allomhc peptide activated t cells.transplantation£¬2001£¬71£º1442-1448.
11 john e.coligan.current protocol in immunology£¬3rd edition.hoboken£ºjohn wiley & sons£¬inc£¬2003.
12 damoiseaux jg£¬cautain b£¬bernard i£¬et al.a dominant role for the thymus and mhc genes in determining the peripheral cd4/cd8 t cell ratio in the rat.j immunol£¬1999£¬163(6)£º2983-2989.